Defibrillation pacing circuitry

Information

  • Patent Grant
  • 9522284
  • Patent Number
    9,522,284
  • Date Filed
    Wednesday, February 24, 2016
    8 years ago
  • Date Issued
    Tuesday, December 20, 2016
    8 years ago
Abstract
Electrical circuit componentry is switchable into a defibrillator circuit to deliver a constant pacing current to a patient. The circuitry may include a constant current source inserted in a leg of the defibrillator circuit or a resistor of selected value inserted between a high voltage source and the high side of a defibrillator circuit.
Description
FIELD

The present invention relates to apparatus and methods useful in connection with performing electrical cardioversion/defibrillation and optional pacing of the heart.


BACKGROUND

Defibrillation/cardioversion is a technique employed to counter arrhythmic heart conditions including some tachycardias in the atria and/or ventricles. Typically, electrodes are employed to stimulate the heart with electrical impulses or shocks, of a magnitude substantially greater than pulses used in cardiac pacing.


Defibrillation/cardioversion systems include body implantable electrodes that are connected to a hermetically sealed container housing the electronics, battery supply and capacitors. The entire system is referred to as implantable cardioverter/defibrillators (ICDs). The electrodes used in ICDs can be in the form of patches applied directly to epicardial tissue, or, more commonly, are on the distal regions of small cylindrical insulated catheters that typically enter the subclavian venous system, pass through the superior vena cava and, into one or more endocardial areas of the heart. Such electrode systems are called intravascular or transvenous electrodes. U.S. Pat. Nos. 4,603,705; 4,693,253; 4,944,300; and 5,105,810, the disclosures of which are all incorporated herein by reference, disclose intravascular or transvenous electrodes, employed either alone, in combination with other intravascular or transvenous electrodes, or in combination with an epicardial patch or subcutaneous electrodes. Compliant epicardial defibrillator electrodes are disclosed in U.S. Pat. Nos. 4,567,900 and 5,618,287, the disclosures of which are incorporated herein by reference. A sensing epicardial electrode configuration is disclosed in U.S. Pat. No. 5,476,503, the disclosure of which is incorporated herein by reference.


In addition to epicardial and transvenous electrodes, subcutaneous electrode systems have also been developed. For example, U.S. Pat. Nos. 5,342,407 and 5,603,732, the disclosures of which are incorporated herein by reference, teach the use of a pulse monitor/generator surgically implanted into the abdomen and subcutaneous electrodes implanted in the thorax. This system is far more complicated to use than current ICD systems using transvenous lead systems together with an active can electrode and therefore it has no practical use. It has in fact never been used because of the surgical difficulty of applying such a device (3 incisions), the impractical abdominal location of the generator and the electrically poor sensing and defibrillation aspects of such a system.


Recent efforts to improve the efficiency of ICDs have led manufacturers to produce ICDs which are small enough to be implanted in the pectoral region. In addition, advances in circuit design have enabled the housing of the ICD to form a subcutaneous electrode. Some examples of ICDs in which the housing of the ICD serves as an optional additional electrode are described in U.S. Pat. Nos. 5,133,353; 5,261,400; 5,620,477; and 5,658,321, the disclosures of which are incorporated herein by reference.


ICDs are now an established therapy for the management of life threatening cardiac rhythm disorders, primarily ventricular fibrillation (V-Fib). ICDs are very effective at treating V-Fib, but are therapies that still require significant surgery.


As ICD therapy becomes more prophylactic in nature and used in progressively less ill individuals, especially children at risk of cardiac arrest, the requirement of ICD therapy to use intravenous catheters and transvenous leads is an impediment to very long term management as most individuals will begin to develop complications related to lead system malfunction sometime in the 5-10 year time frame, often earlier. In addition, chronic transvenous lead systems, their reimplantation and removals, can damage major cardiovascular venous systems and the tricuspid valve, as well as result in life threatening perforations of the great vessels and heart. Consequently, use of transvenous lead systems, despite their many advantages, are not without their chronic patient management limitations in those with life expectancies of >5 years. The problem of lead complications is even greater in children where body growth can substantially alter transvenous lead function and lead to additional cardiovascular problems and revisions. Moreover, transvenous ICD systems also increase cost and require specialized interventional rooms and equipment as well as special skill for insertion. These systems are typically implanted by cardiac electrophysiologists who have had a great deal of extra training.


In addition to the background related to ICD therapy, the present invention requires a brief understanding of a related therapy, the automatic external defibrillator (AED) AEDs employ the use of cutaneous patch electrodes, rather than implantable lead systems, to effect defibrillation under the direction of a bystander user who treats the patient suffering from V-Fib with a portable device containing the necessary electronics and power supply that allows defibrillation. AEDs can be nearly as effective as an ICD for defibrillation if applied to the victim of ventricular fibrillation promptly, i.e., within 2 to 3 minutes of the onset of the ventricular fibrillation.


AED therapy has great appeal as a tool for diminishing the risk of death in public venues such as in air flight. However, an AED must be used by another individual, not the person suffering from the potential fatal rhythm. It is more of a public health tool than a patient-specific tool like an ICD. Because >75% of cardiac arrests occur in the home, and over half occur in the bedroom, patients at risk of cardiac arrest are often alone or asleep and can not be helped in time with an AED. Moreover, its success depends to a reasonable degree on an acceptable level of skill and calm by the bystander user.


What is needed therefore, especially for children and for prophylactic long term use for those at risk of cardiac arrest, is a combination of the two forms of therapy which would provide prompt and near-certain defibrillation, like an ICD, but without the long-term adverse sequelae of a transvenous lead system while simultaneously using most of the simpler and lower cost technology of an AED. What is also needed is a cardioverter/defibrillator that is of simple design and can be comfortably implanted in a patient for many years.


Moreover, it has appeared advantageous to the inventor to provide the capability in such improved circuitry to provide a signal suitable for pacing when the circuitry is not operating in a defibrillation mode.


SUMMARY

Accordingly, the invention relates in various aspects to methods and apparatus for selectively converting a defibrillator circuit or circuit for delivering a defibrillating pulse to a patient into circuitry suitable for providing a constant current, useful, e.g., in pacing applications.





BRIEF DESCRIPTION OF THE DRAWINGS

For a better understanding of the invention, reference is now made to the drawings where like numerals represent similar objects throughout the figures and wherein:



FIG. 1 is a schematic view of a conventional defibrillator circuit;



FIG. 2 is a circuit schematic of an illustrative embodiment of the present invention;



FIG. 3 is a circuit schematic of an alternate embodiment;



FIG. 4 is a circuit schematic of a second alternate embodiment; and



FIGS. 5 and 6 schematically illustrate high side current controlling circuits.



FIG. 7 is an illustrative example of an implantable cardiac device.





DETAILED DESCRIPTION


FIG. 1 illustrates a conventional “H-bridge” defibrillator circuit 11. The circuit 11 includes a capacitor C.sub.1 which is charged to a high voltage V.sub.HV and four switches H.sub.1, H.sub.2, L.sub.1, L.sub.2. The capacitor C.sub.1 and switches H.sub.1, H.sub.2, L.sub.1, L.sub.2 are used to create either a monophasic voltage pulse or a biphasic voltage pulse (FIG. 2) across a patient represented by resistance R.sub.PATIENT. In various applications, the switches H.sub.1, H.sub.2, L.sub.1, L.sub.2, may be MOSFETs, IGBTs, or SCRs (silicon controlled rectifiers).


To create a biphasic waveform such as that shown in FIG. 2, a first pair of switches, e.g., H.sub.1 and L.sub.2, may be closed to create a positive pulse 13. Then all of the switches, H.sub.1, H.sub.2, L.sub.1, L.sub.2, are turned off during a “center pulse” delay period d.sub.1. At the end of the delay period d.sub.1, the switches H.sub.2 and L.sub.1 are both closed, thereby reversing the current through the patient R.sub.PATIENT to produce a negative voltage pulse 17. Typically, digital logic is employed to control the sequencing of the switches H.sub.1, H.sub.2, L.sub.1, L.sub.2. In such cases, the order of the pulses can be inverted, i.e., the negative pulse 17 can be produced before the positive pulse 13. In illustrative applications, the duration of the pulses 13, 17 is, e.g., 1 to 20 milliseconds and the inter-pulse delay d.sub.1 is, e.g., one millisecond.



FIG. 3 illustrates circuitry which may operate as a defibrillator circuit during a first selected interval and as a constant current source during a second selected interval. The constant current may be useful, for example, in providing a “pacing” current to a patient R.sub.PATIENT.


As in FIG. 1, the high side switches H.sub.1, H.sub.2 employed in FIG. 3 may be IGBTs, MOSFETs, SCRs, or other suitable switches. Such high side switches H.sub.1, H.sub.2 may be controlled in any suitable manner such as, for example, with pulse transformers, opto-couplers, photo-voltaic generators, or in accordance with the teachings of U.S. patent application Ser. No. 10/011,957, filed on Nov. 5, 2001 on behalf of the same inventor, now U.S. Pat. No. 6,954,670 and titled SIMPLIFIED DEFIBRILLATOR OUTPUT CIRCUIT, herein incorporated by reference. Digital logic suitable for controlling such circuitry to achieve switching may comprise a programmed microprocessor, microcontroller, discrete logic, or other forms of digital logic control.


In the circuit of FIG. 3, a resistor R.sub.1 is inserted in series with the emitter or the source leg of a first low side transistor Q.sub.2, which is preferably an IGBT or MOSFET. Similarly, a resistor R.sub.2 is inserted in series with the emitter or source leg of the second low side transistor Q.sub.1. A constant voltage is applied across the resistor R.sub.1 via a voltage source, which applies a voltage V.sub.DRIVE to the gate (or base) of the first low side transistor Q.sub.2. During operation of the circuit of FIG. 2 as a defibrillator, the transistors Q.sub.1, Q.sub.2 serve the purposes of low side switches, e.g., L.sub.1, L.sub.2 of FIG. 1, and the resistors R.sub.1, R.sub.2 are switched out of the circuit by suitable means, e.g., switches SW.sub.1 and SW.sub.2. During pacing operation of the circuit of FIG. 3, a suitable switching signal is applied to switch resistor R.sub.1 into the circuit.


In an illustrative application of the circuitry of FIG. 3, the low side transistors Q.sub.1, Q.sub.2 may be high voltage IGBTs or MOSFETs, ranging from 500 volts to 3,000 volts capacity or greater. In the circuit of FIG. 3, the voltage across the resistor R.sub.1 is defined by the equation:

V.sub.R1=V.sub.DRIVE-V.sub.T  (1)

where V.sub.T is the fixed (constant) threshold voltage of the low side transistor Q.sub.1. Thus, if V.sub.DRIVE is 15 volts, and V.sub.T is in the range of 2-6 volts, V.sub.R1 is in the range of 13 to 9 volts. Accordingly, a constant voltage is applied across the resistor R.sub.1, resulting in a constant current I.sub.RI through the resistor R.sub.1, and hence through the patient R.sub.PATIENT.


As those skilled in the art may appreciate, the threshold voltage V.sub.T of the transistor Q.sub.1 may vary from device to device. Hence, it is typically necessary to calibrate the circuit in production. In calibrating a circuit like that of FIG. 3, a known voltage is applied and the current through R.sub.1 is measured, typically resulting in a large offset, which is compensated for by the system software.


In order to avoid calibration, the voltage source may be constructed using a feedback circuit employing an operational amplifier as shown in FIG. 4. The op-amp is connected to directly drive the low side transistor Q.sub.2, which may comprise, e.g., a MOSFET or IGBT. Use of the operational amplifier removes the uncertainty of the threshold voltage V.sub.T so that the current that passes through the resistor R.sub.1 is equal to simply V.sub.DRIVE divided by R.sub.1. Thus, one can either drive the transistor Q.sub.2 with a voltage source and calibrate the system for the V.sub.T of the transistor Q.sub.2 or use an op-amp circuit to remove the error created by the threshold voltage V.sub.T of the transistor Q.sub.2.


During constant current source operation of the circuit of FIG. 4, the appropriate high side switch is on to permit current flow. In addition, the capacitor voltage V.sub.c needs to be appropriately selected according to a number of considerations. First, the current that is programmed to go through the patient will generate a voltage V.sub.PATIENT across the patient. Then, in order to make the current source work, the voltage compliance V.sub.COMP of the current source must be appropriately set. In the case of FIG. 4, the voltage compliance V.sub.COMP is the voltage V.sub.R1 across the resistor R.sub.1 plus the minimum operating voltage V.sub.T of the low side transistor Q.sub.2. Accordingly, the minimum voltage V.sub.HV across the capacitor C.sub.1 is defined by the relation:

V.sub.HV(min.)=V.sub.PATIENT+V.sub.COMP  (2)


The higher V.sub.HV is above V.sub.HV (min.), the closer the current source will approach an ideal current source. Another consideration in setting V.sub.HV is power consumption.


The amount of current I.sub.R1 can be varied by varying the voltage V.sub.DRIVE or by switching in different resistors, e.g., in series with or for R.sub.1. From an implementation point of view, it is less attractive to switch in a resistor because such switching requires adding transistors or other switching devices. It is more efficient to simply vary the voltage V.sub.DRIVE. Suitable logic circuitry may be provided to select the value of V.sub.DRIVE. A DAC (digital to analog converter) is one example of such logic circuitry. As those skilled in the art will appreciate, a DAC is a circuit that generates different voltages in response to corresponding digital codes provided to it. Such a DAC could be used to drive either an input of the op-amp A (as illustrated in FIG. 4) or the input (gate) of the transistor Q.sub.1. As noted above, an advantage of the op-amp A is that it removes the V.sub.T term from the V.sub.HV equation. Particular parameter ranges for circuitry as configured in FIGS. 3 and 4 include 1 to 50 ohms for the resistance R.sub.1 and 1 to 20 volts for a V.sub.DRIVE resulting in a current ranging from 0 to 500 milliamps.


Another illustrative circuit for implementing a current source is illustrated in FIG. 5. This circuit employs a resistor R.sub.3 connected between the high voltage capacitor C.sub.1 and the high side switches H.sub.1, H.sub.2. The resistor R.sub.3 is switched out of the circuit by a switch SW.sub.3 for defibrillator operation and into the circuit for pacing.


The circuit of FIG. 5 is somewhat more energy wasteful but will work with the use of a high voltage switch for SW.sub.3. In the circuit of FIG. 5, the switches H.sub.1, H.sub.2, L.sub.1, L.sub.2 are manipulated so as to place the resistor R.sub.3 in series with the output. The amount of current may then be selected by the voltage to which the capacitor C.sub.1 is charged. As an example, assuming the patient resistance R.sub.PATIENT varies from 30-150 ohms, selecting a resistor R.sub.3 of anywhere from 500-5000 ohms, i.e., a resistance that is much larger than that of the patient, results in an approximation of an ideal current source. The approximation is:

i=VHVR3+R PATIENT  (3)##EQU00001##


While creation of a current source according to FIG. 5 is relatively easy, switching the circuit to the defibrillation mode is more complex. As shown in FIG. 6, a high voltage switch SW.sub.3 is connected across the series resistor R.sub.3 to switch R.sub.3 out of the circuit in order to enter the defibrillation mode. Since the high voltage switch SW.sub.3 is a floating switch, a high side driver 19 is also needed. These considerations render the circuit of FIG. 6 more difficult to implement in an implantable device.


In contrast, the circuits of FIGS. 3 and 4 require a switch, e.g., SW.sub.1 to switch to the defibrillation mode, but the switch SW.sub.1 does not have to be a high voltage switch. Instead, the switch SW.sub.1 need only be a smaller, low voltage device having the capacity to pass the defibrillation current. In an illustrative circuit, there may be on the order of only 10 volts across SW.sub.1, which is advantageous.


Thus, only a low voltage switch need be used in the circuits of FIGS. 3 and 4. No low voltage driver is necessary since the switch SW.sub.1 is referenced to ground and can therefore be driven directly. A high side driver circuit is unnecessary. In either of the circuits of FIG. 3 or FIG. 4, the voltage V.sub.DRIVE is preferably implemented by a DAC, either connected to directly drive the resistor R.sub.1 (FIG. 3) or to drive the resistor R.sub.3 through an op-amp A (FIG. 4).


Provision of a constant current has the advantage of maintaining a constant current density across the heart, irrespective of the electrode interface impedance.



FIG. 7 illustrates an implantable cardiac device 100. The implantable cardiac device includes a housing 102 for containing the operational circuitry of the device. Attached to the housing 102 is a lead 104 carrying a plurality of electrodes 106. The implantable cardiac device 100 is merely illustrative of one design for an implantable device. The housing 102 may, if desired, be an active housing having an electrode for stimulus delivery or sensing. Other details of the implantable cardiac device 100 are found in U.S. Pat. No. 6,721,597, which is incorporated herein by reference.


While the present invention has been described above in terms of specific embodiments, it is to be understood that the invention is not limited to the disclosed embodiments. On the contrary, the following claims are intended to cover various modifications and equivalent methods and structures included within the spirit and scope of the invention.

Claims
  • 1. An implantable cardiac stimulus system comprising: implantable electrodes for the delivery of electrical stimulus to a patient;operational circuitry including at least an H-bridge circuit comprising a high side and a low side, wherein the H-bridge circuit comprises first and second legs connected between the high side and the low side thereof, wherein the first leg of the H-bridge circuit comprises first and second current switching elements and the second leg of the H-bridge circuit comprises third and fourth current switching elements, the H-bridge comprising output nodes for coupling to patient tissue via the implantable electrodes, wherein a first output node is located on the first leg between the first and second current switching elements and a second output node is located on the second leg between the third and fourth current switching elements, the operational circuitry further comprising a constant current circuit connected to the low side of the H-bridge circuit anda canister for housing at least the battery and operational circuitry;wherein the first and fourth current switching elements define a first pair of current switching elements;wherein the operational circuitry is configured to select the first pair of current switching elements to generate a stimulus of a first polarity for application via the first and second output nodes; andwherein the constant current circuit comprises a bypass switch and a pacing resistor in parallel with one another and coupled to the low side of the H-bridge;wherein the operational circuitry is configured to close the bypass switch to deliver a defibrillation output, and to open the bypass switch to force current from the low side of the H-bridge through the pacing resistor to deliver a pacing output andwherein the constant current circuit is configured to control operation of the fourth current switching element by monitoring a voltage across the pacing resistor during a stimulus of the first polarity to force the stimulus to be a substantially constant current pacing stimulus.
  • 2. The implantable system of claim 1 wherein: in the first leg of the H-bridge, the first current switching element links the high side of the H-bridge to the first output node and the second current switching element links the low side of the H-bridge to the first output node;in the second leg of the H-bridge, the third current switching element links the high side of the H-bridge to the second output node and the fourth current switching element links the low side of the H-bridge to the second output node;the constant current circuit includes an amplifier for generating a control signal output to the fourth switching element.
  • 3. The implantable system of claim 2 wherein the operational circuitry is configured to generate the substantially constant current pacing therapy by applying a first voltage to the high side of the H-bridge, closing the first switch, and applying the control signal output to the fourth switch.
  • 4. The implantable system of claim 3 wherein the operational circuitry further comprises a therapy circuit with a high power capacitor for use in delivering either pacing or defibrillator therapy, such that the first voltage is received from the high power capacitor.
RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 12/426,779, filed Apr. 20, 2009 and titled DEFIBRILLATION PACING CIRCUITRY, now U.S Patent No. 9,283,398, which is a continuation of U.S. patent application Ser. No. 11/146,607, filed Jun. 7, 2005, now U.S. Pat. No. 7,522,957 and titled DEFIBRILLATION PACING CIRCUITRY, which is a continuation of U.S. patent application Ser. No. 10/011,955, filed Nov. 5, 2001, now U.S. Pat. No. 6,952,608 and titled DEFIBRILLATION PACING CIRCUITRY, the entire disclosures of which are incorporated herein by reference. The invention of the present application may find application in systems such as is disclosed in U.S. Pat. No. 6,721,597, titled SUBCUTANEOUS ONLY IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR AND OPTIONAL PACER, and U.S. Pat. No. 6,647,292, titled UNITARY SUBCUTANEOUS ONLY IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR AND OPTIONAL PACER, and the disclosures of both applications are hereby incorporated by reference. In addition, the foregoing applications are related to: [0004] U.S. patent application Ser. No. 09/940,283, filed Aug. 27, 2001, now U.S. Pat. No. 7,065,407 and titled DUCKBILL-SHAPED IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR CANISTER AND METHOD OF USE; [0005] U.S. patent application Ser. No. 09/940,371, filed Aug. 27, 2001, now U.S. Pat. No. 7,039,465 and titled CERAMICS AND/OR OTHER MATERIAL INSULATED SHELL FOR ACTIVE AND NON-ACTIVE S-ICD CAN; [0006] U.S. patent application Ser. No. 09/940,468, filed Aug. 27, 2001, published as US 2002-0035379 A1 and titled SUBCUTANEOUS ELECTRODE FOR TRANSTHORACIC CONDUCTION WITH IMPROVED INSTALLATION CHARACTERISTICS; [0007] U.S. patent application Ser. No. 09/941,814, filed Aug. 27, 2001, published as US 2002-0035381 A1 and titled SUBCUTANEOUS ELECTRODE WITH IMPROVED CONTACT SHAPE FOR TRANSTHORACIC CONDUCTION; [0008] U.S. patent application Ser. No. 09/940,356, filed Aug. 27, 2001, published as US 2002-0035378 A1 and titled SUBCUTANEOUS ELECTRODE FOR TRANSTHORACIC CONDUCTION WITH HIGHLY MANEUVERABLE INSERTION TOOL; [0009] U.S. patent application Ser. No. 09/940,340, filed Aug. 27, 2001, now U.S. Pat. No. 6,937,907 and titled SUBCUTANEOUS ELECTRODE FOR TRANSTHORACIC CONDUCTION WITH LOW-PROFILE INSTALLATION APPENDAGE AND METHOD OF DOING SAME; [0010] U.S. patent application Ser. No. 09/940,287, filed Aug. 27, 2001, published as US 2002-0035377 A1 and titled SUBCUTANEOUS ELECTRODE FOR TRANSTHORACIC CONDUCTION WITH INSERTION TOOL; [0011] U.S. patent application Ser. No. 09/940,377, filed Aug. 27, 2001, now U.S. Pat. No. 6,866,044 and titled METHOD OF INSERTION AND IMPLANTATION OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR CANISTERS; [0012] U.S. patent application Ser. No. 09/940,599, filed Aug. 27, 2001, now U.S. Pat. No. 6,950,705 and titled CANISTER DESIGNS FOR IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; [0013] U.S. patent application Ser. No. 09/940,373, filed Aug. 27, 2001, now U.S. Pat. No. 6,788,974 and titled RADIAN CURVE SHAPED IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR CANISTER; [0014] U.S. patent application Ser. No. 09/940,273, filed Aug. 27, 2001, now U.S. Pat. No. 7,069,080 and titled CARDIOVERTER-DEFIBRILLATOR HAVING A FOCUSED SHOCKING AREA AND ORIENTATION THEREOF; [0015] U.S. patent application Ser. No. 09/940,378, filed Aug. 27, 2001, now U.S. Pat. No. 7,146,212 and titled BIPHASIC WAVEFORM FOR ANTI-BRADYCARDIA PACING FOR A SUBCUTANEOUS IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; and [0016] U.S. patent application Ser. No. 09/940,266, filed Aug. 27, 2001, now U.S. Pat. No. 6,856,835 and titled BIPHASIC WAVEFORM FOR ANTI-TACHYCARDIA PACING FOR A SUBCUTANEOUS IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR, the entire disclosures of which are incorporated herein by reference.

US Referenced Citations (75)
Number Name Date Kind
3653387 Ceier Apr 1972 A
3710374 Kelly Jan 1973 A
4191942 Long Mar 1980 A
4223678 Langer et al. Sep 1980 A
4402322 Duggan Sep 1983 A
4407288 Langer et al. Oct 1983 A
4567900 Moore Feb 1986 A
4602637 Elmqvist et al. Jul 1986 A
4603705 Speicher et al. Aug 1986 A
4693253 Adams Sep 1987 A
4800883 Winstrom Jan 1989 A
4830005 Woskow May 1989 A
4944300 Saksena Jul 1990 A
5105810 Collins et al. Apr 1992 A
5109842 Adinolfi May 1992 A
5129392 Bardy et al. Jul 1992 A
5133353 Hauser Jul 1992 A
5144946 Weinberg et al. Sep 1992 A
5184616 Weiss Feb 1993 A
5261400 Bardy Nov 1993 A
5331966 Bennett et al. Jul 1994 A
5342407 Dahl et al. Aug 1994 A
5376103 Anderson et al. Dec 1994 A
5376104 Sakai et al. Dec 1994 A
5411547 Causey, III May 1995 A
5413591 Knoll May 1995 A
5476503 Yang Dec 1995 A
5507781 Kroll et al. Apr 1996 A
5531765 Pless Jul 1996 A
5601607 Adams Feb 1997 A
5603732 Dahl et al. Feb 1997 A
5618287 Fogarty et al. Apr 1997 A
5620477 Pless et al. Apr 1997 A
5645572 Kroll et al. Jul 1997 A
5658317 Haefner et al. Aug 1997 A
5658321 Fayram et al. Aug 1997 A
5674260 Weinberg Oct 1997 A
5690683 Haefner et al. Nov 1997 A
5697953 Kroll et al. Dec 1997 A
5713926 Hauser et al. Feb 1998 A
5718242 McClure et al. Feb 1998 A
5766226 Pedersen Jun 1998 A
5836976 Min et al. Nov 1998 A
5919211 Adams Jul 1999 A
5935154 Westlund Aug 1999 A
5941904 Johnston et al. Aug 1999 A
6014586 Weinberg et al. Jan 2000 A
6026325 Weinberg et al. Feb 2000 A
6058328 Levine et al. May 2000 A
6096063 Lopin et al. Aug 2000 A
6104953 Leyde Aug 2000 A
6128531 Campbell-Smith Oct 2000 A
6144866 Miesel et al. Nov 2000 A
6169921 KenKnight et al. Jan 2001 B1
6185450 Seguine et al. Feb 2001 B1
6208895 Sullivan Mar 2001 B1
6241751 Morgan et al. Jun 2001 B1
6411844 Kroll et al. Jun 2002 B1
6647292 Bardy et al. Nov 2003 B1
6721597 Bardy et al. Apr 2004 B1
6778860 Ostroff et al. Aug 2004 B2
6788974 Bardy et al. Sep 2004 B2
6856835 Bardy et al. Feb 2005 B2
6866044 Bardy et al. Mar 2005 B2
6937907 Bardy et al. Aug 2005 B2
6950705 Bardy et al. Sep 2005 B2
6952608 Ostroff Oct 2005 B2
6954670 Ostroff Oct 2005 B2
7039465 Bardy et al. May 2006 B2
7065407 Bardy et al. Jun 2006 B2
7069080 Bardy et al. Jun 2006 B2
7146212 Bardy et al. Dec 2006 B2
7389139 Ostroff Jun 2008 B2
20010027330 Sullivan et al. Oct 2001 A1
20030088283 Ostroff May 2003 A1
Foreign Referenced Citations (20)
Number Date Country
0316616 May 1989 EP
0347353 Dec 1989 EP
0518599 Dec 1992 EP
0641573 Mar 1995 EP
0641573 Jun 1997 EP
0518599 Sep 1997 EP
0536873 Sep 1997 EP
0917887 May 1999 EP
0923130 Jun 1999 EP
9319809 Oct 1993 WO
9825349 Jun 1998 WO
9903534 Jan 1999 WO
9937362 Jul 1999 WO
0156166 Aug 2001 WO
0222208 Mar 2002 WO
0224275 Mar 2002 WO
0224275 May 2002 WO
0222208 Jun 2002 WO
02068046 Sep 2002 WO
03018121 Mar 2003 WO
Non-Patent Literature Citations (14)
Entry
Bardy et al., “Multicenter Experience with a Pectoral Unipolar Implantable Cardioverter-Defibrillator”, JACC, vol. 28(2), pp. 400-410, Aug. 1996.
Friedman et al., “Implantable Defibrillators in Children: From Whence to Shock,” Journal of Cardiovascular Electrophysiology, vol. 12(3), pp. 361-362, Mar. 2001.
Gradaus et al., “Nonthoracotomy Implantable Cardioverter Defibrillator Placement in Children: Use of Subcutaneous Array Leads and Abdominally Placed Implantable Cardiovascular Defibrillators in Children,” Journal of Cardiovascular Electrophysiology, vol. 12(3) pp. 356-360, Mar. 2001.
Higgins et al., “The First Year Experience with the Dual Chamber ICD,” PACE, vol. 23, pp. 18-25, Jan. 2000.
Mirowski et al., “Automatic Detection and Defibrillation of Lethal, Arrhythmias—A new Concept,” JAMA, vol. 213(4), pp. 615-616, Jul. 27, 1970.
Olson et al., “Onset and Stability for Ventricular Tachyarrhythmia Detection in an Implantable Pacer-Cardioverter-Defibrillator,” IEEE, pp. 167-170, 1987.
Schuder et al., “Experimental Ventricular Defibrillation with an Automatic and Completely Implanted System,” Trans. Amer. Soc. Artif. Int. Organs, vol. XVI, pp. 207-212, 1970.
Schuder, “The role of an Engineering Oriented Medical Research Group in Developing Improved Methods and Devices for Achieving Ventricular Defibrillation: The University of Missouri Experience,” PACE, vol. 16, pp. 95-123, Jan. 1993.
Schuder et al., “Standby Implanted Defibrillators,” Arch Intern. Med., vol. 127, p. 317 (single sheet), Feb. 1971.
Schuder et al., “Transthoracic Ventricular Defibrillation in the Dog with Truncated and Untruncated Exponential Stimuli,” IEEE Transactions of Bio-Medical Engineering, vol. BME 18(6).
Schwacke et al., “Komplikationen mit Sonden bei 340 Patienten mit einem Implantierbaren Kardioverter/Defibrillator,” Z Kardiol, vol. 88(8), pp. 559-565, 1999.
Tietze et al., “Halbleiter-Schaltungstechnik,” Springer-Verlag, Berlin, Germany, pp. 784-786, 1991.
Valenzuela et al., “Outcomes of Rapid Defibrillation by Security Offices After Cardiac Arrest in Casinos,” The New England Journal of Medicine, vol. 343(17), pp. 1206-1209, Oct. 26, 2000.
Walters et al., “Analog to Digital Conversion Techniques in Implantable Devices,” Annual Internaational Conference of the IEEE Engineering in Medicine and Biology Society, vol. 13(4), pp. 1674-1676, 1991.
Related Publications (1)
Number Date Country
20160166841 A1 Jun 2016 US
Continuations (3)
Number Date Country
Parent 12426779 Apr 2009 US
Child 15051805 US
Parent 11146607 Jun 2005 US
Child 12426779 US
Parent 10011955 Nov 2001 US
Child 11146607 US